Aqara Launches Its First Smart Wall Switch for Europe
22.6.2021 11:00:00 EEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first smart wall switch targeted for the European market, the Aqara Smart Wall Switch H1 EU. The Wall Switch H1 EU series is Aqara’s first smart wall switch supporting both round European wall boxes and 86 mm square wall boxes. It’s available in Single and Double Rocker versions, as well as in With Neutral and No Neutral versions. Along with the Wall Switch H1 EU, Aqara also introduced the latest Wireless Remote Switch H1 (Double Rocker) to the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005459/en/
Aqara Smart Wall Switch H1 EU and Aqara Wireless Switch H1 (Photo: Aqara)
Both the Wall Switch H1 EU and the Wireless Switch H1 support the Zigbee 3.0 protocol with better stability, compatibility, responsiveness and energy efficiency1. Both switches share the award-wining design with a metal frame, which makes the switches more rigid and durable. Moreover, the combination of the Wall Switch H1 EU and the Wireless Switch H1 can be used in a 2-way switch setup without excessive wiring, or to upgrade the existing 2-way setup to a smart one, so that users will be able to control the light or other device from two different places similar to using two hard-wired 2-way switches, or even from any part of the room by voice commands or via local automations.
The Wall Switch H1 EU is compatible with major smart home ecosystems and voice assistants, including Apple HomeKit, Amazon Alexa, Google Assistant, IFTTT, and more2. The availability of With Neutral and No Neutral versions makes it fit almost all homes, while the With Neutral version supports extra features such as power monitoring and overload protection. Other features of the Wall Switch H1 EU include:
- Convert to Wireless Switch Function: The button of the switch can be remapped so that you will get an extra “wireless switch” while the light or other device will be controlled by automations;
- Overheat Protection: Users can be ensured that their homes are safe and secure;
- LED Indicator Behavior Setting: Users can configure the LED indicator via the Aqara Home app, choosing to turn it off completely, turn it on when the switch is on, or vice versa3.
The Wireless Switch H1 is a HomeKit-compatible remote switch to control Aqara devices and other HomeKit accessories or to switch between smart home scenes. It comes with a double rocker, and recognizes 7 configurable actions including single click, double click, long press, and dual-button press. It also supports the High-Speed Click Mode, which reduces the response time down to 50 milliseconds4. The Wireless Switch H1 also features a 5-year battery life, the longest so far among all Aqara battery-powered devices.
The Wall Switch H1 EU and the Wireless Switch H1 are expected to be available in various European and Asian countries via authorized Aqara distributors in the following months. Please check with your regional distributor(s) for product availability.
For more details of the Wall Switch H1 EU and the Wireless Switch H1, please visit our website.
|
1 |
A compatible Zigbee 3.0 Aqara hub (including Hub M1S, Hub M2 and Camera Hub G2H) is required. |
|
|
2 |
Integration with some third-party ecosystems may be unavailable by the time of the launch. |
|
|
3 |
Not all of these options are available for the No Neutral version. |
|
|
4 |
Only single clicks are recognized in the High-Speed Click Mode. |
About Aqara
Founded in 2016, Aqara is a leading smart home provider with offices in New York and Shenzhen. We provide comprehensive smart home products and solutions that are beautifully designed, affordable and easy to use. Our products range from a variety of sensors to switches, curtain controllers, and door locks, and we have opened more than 400 Aqara Home stores globally to provide more personalized smart home solutions.
We continue to expand our global footprint in the United States, EU, Russia, Southeast Asia, Korea and China, and our online devices have covered 192 countries and territories, serving more than 2 million customers. We aspire to bring smart home technology to every household around the world.
For more information, please visit our website and follow our social platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005459/en/
Contact information
For Media Enquiry:
Michell Li
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom